top of page
gradientForSurfBreak.png

Item List

PR Newswire
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

Invitae ( NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's Ciitizen platform were utilized as natural history data to support the submission of Praxis' Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE). Praxis announced earlier this month that the U.S. Food and Drug Administration (FDA) cleared the IND application for the initial dose cohort for the PRAX-222 EMBRAVE clinical study.

Recent Posts

Portfolio Company

Carlsmed.png

Clario and Strados Labs partner to bring new pulmonary endpoints to respiratory ...

Strados Labs

Wavemaker 360 News

Carlsmed.png

Wavemaker Three-Sixty Health Announces 2023 Council of Strategic Advisors to Sup ...

Businesswire

Wavemaker 360 News

Carlsmed.png

MedTech Color investing in Black, brown leaders in medical technology world ...

Fox 11 News

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page